Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.26

0.865 (2.67%)

, TEVA

Teva

$32.79

-0.396 (-1.19%)

13:58
07/14/17
07/14
13:58
07/14/17
13:58

AstraZeneca up 4% after Bloomberg says CEO plans on staying

Shares of Teva (TEVA) are down 4% to $31.97.

AZN

AstraZeneca

$33.26

0.865 (2.67%)

TEVA

Teva

$32.79

-0.396 (-1.19%)

  • 19

    Jul

  • 03

    Aug

  • 30

    Aug

AZN AstraZeneca
$33.26

0.865 (2.67%)

07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
TEVA Teva
$32.79

-0.396 (-1.19%)

06/27/17
WELS
06/27/17
NO CHANGE
WELS
Market Perform
Teva TV-45070 trial miss a 'modest disappointment,' says Wells Fargo
Wells Fargo analyst David Maris said TV-45070 has not been a focus for Teva (TEVA) investors, but he still views the news that the company and partner Xenon Pharmaceuticals' (XENE) Phase 2 trial in post-herpetic neuralgia missed its primary endpoint as a "modest disappointment" given the need for Teva's pipeline to offset the tough generic market and the eventual competition for Copaxone. Maris keeps a Market Perform rating on Teva.
07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.

TODAY'S FREE FLY STORIES

TYPE

Monotype Imaging

$18.45

-0.35 (-1.86%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Monotype Imaging reports Q2 adjusted EPS 8c, consensus 9c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CMS

CMS Energy

$46.89

0.36 (0.77%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Earnings
CMS Energy reports Q2 EPS 33c, consensus 39c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Recommendations
Heritage Commerce analyst commentary  »

Heritage Commerce premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

JPM

JPMorgan

$91.55

-0.38 (-0.41%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
JPMorgan says to be 100% reliant on renewable energy by 2020 »

JPMorgan Chase is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

HRC

Hill-Rom

$79.70

-2.88 (-3.49%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Hill-Rom reports Q3 adj. EPS 91c, consensus 91c »

Reports Q3 revenue $689M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 06

    Aug

  • 10

    Aug

  • 15

    Aug

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax raises FY17 adjusted EPS view to $1.65-$1.75 from $1.60-$1.75 

Consensus $1.73.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax reports Q2 adjusted EPS 43c, consensus 43c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

DVAX

Dynavax

$9.25

-1.15 (-11.06%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
Breaking Hot Stocks news story on Dynavax »

Dynavax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 31

    Jul

  • 10

    Aug

EA

Electronic Arts

$117.60

-0.4 (-0.34%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

UFS

Domtar

$38.49

0.06 (0.16%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Earnings
Domtar reports Q2 EPS 61c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$11.83

-0.07 (-0.59%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Periodicals
Fiat Chrysler's Maserati to launch electric model after 2019, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$45.16

-0.57 (-1.25%)

06:57
07/28/17
07/28
06:57
07/28/17
06:57
Earnings
Valero Energy Partners reports Q2 EPS 69c, consensus 75c »

Reports Q2 revenue $110M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

ZBH

Zimmer Biomet

$125.44

-3.26 (-2.53%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Zimmer Biomet rating change  »

Zimmer Biomet downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

JCI

Johnson Controls

$40.14

-3.18 (-7.34%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Johnson Controls rating change  »

Johnson Controls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 08

    Aug

X

U.S. Steel

$25.00

-1.2 (-4.58%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
U.S. Steel rating change  »

U.S. Steel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck reports Q2 KEYTRUDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VC

Visteon

$111.53

1.56 (1.42%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
QEP Resources rating change  »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MRK

Merck

$63.69

1.89 (3.06%)

06:52
07/28/17
07/28
06:52
07/28/17
06:52
Hot Stocks
Merck CEO Q2 results driven by 'robust momentum for KEYTRUDA' »

"We continued to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

PLT

Plantronics

$53.65

0.15 (0.28%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Downgrade
Plantronics rating change  »

Plantronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

VLKAY

Volkswagen

$31.69

-0.66 (-2.04%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Periodicals
California approves Volkswagen's clean vehicle infrastructure plan, Reuters says »

The California Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSH

NuStar GP Holdings

$23.55

0.05 (0.21%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Earnings
Breaking Earnings news story on NuStar GP Holdings »

NuStar GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

MRK

Merck

$63.69

1.89 (3.06%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VFC

VF Corp.

$60.81

-0.06 (-0.10%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.